1. Introduction {#sec1-molecules-24-01741}
===============

It is not coincidental that the first effective antibiotics used to treat microbes (the penicillins, [Figure 1](#molecules-24-01741-f001){ref-type="fig"}) contains a thiazole ring. Also, several commercial drugs for various types of diseases that contain thiazole moieties, were synthesized, as illustrated in [Figure 1](#molecules-24-01741-f001){ref-type="fig"}. Thiazole derivatives are actually a considerable group of heterocyclic compound that have therapeutic effects against several diseases \[[@B1-molecules-24-01741],[@B2-molecules-24-01741]\]. The most pertinent and modern studies have manifested that these molecules display antifungal \[[@B3-molecules-24-01741]\], antibacterial \[[@B4-molecules-24-01741]\], anti-inflammatory \[[@B5-molecules-24-01741],[@B6-molecules-24-01741]\], analgesic \[[@B7-molecules-24-01741]\], and anti-cancer \[[@B8-molecules-24-01741],[@B9-molecules-24-01741]\] activities. Many patents have been registered for thiazole compounds with antimicrobial activity \[[@B10-molecules-24-01741],[@B11-molecules-24-01741]\]. It has been demonstrated that the design and synthesis of organic compounds containing more than one thiazole ring unit enhanced their therapeutic activities \[[@B12-molecules-24-01741],[@B13-molecules-24-01741],[@B14-molecules-24-01741],[@B15-molecules-24-01741]\]. Thus, many researchers have become interested in the synthesis of molecules containing more than one thiazole moiety \[[@B16-molecules-24-01741],[@B17-molecules-24-01741]\]. Also, as a result of persistent microbial resistance to antibiotics, chemical and pharmaceutical researchers are constantly seeking to discover and synthesize alternatives to known antibiotics. Thus, from viewpoint of the promising antimicrobial activity of thiazoles and in continuation to our efforts concerning the synthesis of bioactive heterocyclic compounds \[[@B18-molecules-24-01741],[@B19-molecules-24-01741],[@B20-molecules-24-01741],[@B21-molecules-24-01741],[@B22-molecules-24-01741],[@B23-molecules-24-01741],[@B24-molecules-24-01741]\], herein, we aimed to synthesize a new series of compounds having more than one thiazole ring. This was executed via the reaction of 2-bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one with different heterocyclic amines and thiosemicarbazones. Due to the possibility of formation of more than one isomer from the reaction of heterocyclic amines with the phenacyl bromide derivative, we aimed to elucidate the actual structural forms through various techniques. Moreover, the antimicrobial activity of the products was screened against different types of bacteria and fungi and simulated by docking processes for some chosen conformers.

2. Results and Discussion {#sec2-molecules-24-01741}
=========================

2.1. Chemistry {#sec2dot1-molecules-24-01741}
--------------

The starting material required in this study was 2-bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one (**2**), which was prepared through bromination of 5-acetyl-4-methyl-2-(methylamino)thiazole (**1**) in acidic medium, as previously reported \[[@B25-molecules-24-01741]\] ([Scheme 1](#molecules-24-01741-sch001){ref-type="scheme"}). The phenacyl bromide derivative **2** was reacted with a mole equivalent of 2-aminothiazole (**3**) in ethanol under reflux to give one of two possible isomers **6A** or **6B** as indicated by the presence of only one spot in TLC. The spectral data (IR, MS) and elemental analysis cannot distinguish the actual product among the suggested possibilities. ^1^H-NMR of the isolated product showed a remarkable singlet at *δ* = 8.20 ppm for the imidazole proton. The high value of such a chemical shift indicated that this =CH is adjacent to a sp^3^ hybridized nitrogen atom \[[@B26-molecules-24-01741],[@B27-molecules-24-01741]\], which is possible in isomer **6A** rather than isomer **6B**. As illustrated in [Scheme 2](#molecules-24-01741-sch002){ref-type="scheme"}, the reaction proceeds via the formation of an iminothiadiazole intermediate **I**, followed by in-situ dehydrative cyclization to form the desired fused heterocycle **6A** \[[@B19-molecules-24-01741]\]. Dalimba et al., also proved this route using X-ray crystallographic analysis, that indicated the elimination of HBr from the endo-NH group, while, the exocyclic-NH group condensed with a carbonyl group to lose H~2~O \[[@B27-molecules-24-01741]\]. 2-Aminobenzothiazole (**4**) reacted in a similar way with compound **2** to afford 5-(benzo\[*d*\]imidazo \[2,1-*b*\]thiazol-2-yl)-*N*,4-dimethylthiazol-2-amine (**7A**). The other possible isomer **7B** ([Scheme 1](#molecules-24-01741-sch001){ref-type="scheme"}), was discarded based on ^1^H-NMR data and a conformational study, that will discussed later. As for instance, the ^1^H-NMR spectrum of the isolated product showed a characteristic singlet signal at *δ* = 8.76 ppm for the imidazole-H proton of isomer **7A**. 5-(4*H*-Benzo\[*b*\]\[1,4\]thiazin-3-yl)-*N*,4-dimethylthiazol-2-amine (**8A**) was formed via reaction of 2-aminothiophenol with 2-bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one (**2**) in ethanol under reflux ([Scheme 1](#molecules-24-01741-sch001){ref-type="scheme"}). The formation of isomer **8A** instead of **8B** agrees with the fact that the nucleophilicity of the sulfur atom is more than that of the NH~2~ group thus, the reaction started with S-alkylation with the elimination of HBr, followed by concurrent removal of a water molecule from NH~2~ and the carbonyl group. Moreover, the mass spectra of new derivatives **6**, **7** and **8** displayed the correct molecular ions as suggested for their molecular formulae (see Experimental part). Furthermore, the IR spectra for all derivatives **6**--**8** were free from any absorption bands characteristic for C=O, but, revealed the presence of two characteristic bands for NH and C=N at 3417-3238 and 1634-1612 cm^−1^, respectively.

Other heterocyclic amines namely, 5-aminotetrazole **9**, 2-aminobenzimidazole **10**, and 3-amino-1,2,4-triazole **11** reacted with compound **2** to give new series of thiazole rings carrying different azoles at position 5, indicated by numbers **12**--**14**, respectively ([Scheme 3](#molecules-24-01741-sch003){ref-type="scheme"}). In this case, none of the spectral data (MS, IR and NMR) can discriminate between the two possible isomers **12A** and **12B**, while the structural modeling study can do that. For instance, its IR-data are in agreement with the two suggested structures **12A** and **12B**, which are free from any C=O absorption bands and have notable bands for NH and C=N groups.

Based on the high reactivity of α-bromoketone derivative **2**, it was further reacted with pyrimidine thiones **15a**,**b** in dioxane in the presence of a catalytic amount of Et~3~N to afford one of three isomers **17A**, **17B** or **17C** ([Scheme 4](#molecules-24-01741-sch004){ref-type="scheme"}). The preliminary choice for the actual product of reaction, was based on the ^13^C-NMR spectrum, that revealed the presence of a remarkable signal for the C=O group carbon at *δ* 166.7 ppm, a value that indicated that the carbonyl group was adjacent to a sp^3^ nitrogen atom \[[@B28-molecules-24-01741]\] as in the two isomers **17A** and **17C**. The IR of the product **17a** (R = Ph)**,** displayed significant bands at, ύ = 3430 (NH) and 1653 (C=O), which suggested the presence of **17A** tautomer in the solid state, while, the ^1^H-NMR spectrum suggested the existence of **17C** tautomer, through the appearance of a singlet signal for the CH~2~ group at *δ* = 4.44 ppm and lack of from any signals for a NH group ([Figure 2](#molecules-24-01741-f002){ref-type="fig"}), while the other derivative **17b** (R = CH~3~) exists in only the tautomeric form **17A** as proved from its spectral data (see Experimental part). The formation of products **17a**,**b** started with substitution reactions through the formation of intermediate **16**, which was followed by concurrent elimination of a water molecule ([Scheme 4](#molecules-24-01741-sch004){ref-type="scheme"}).

The simple and easy synthesis of more than one thiazole ring in molecules was achieved by the reaction of thiasemicarbazone derivatives **18a**--**f**, **20a**,**b**, **22** and **23** with α-bromoketone derivative **2** ([Scheme 5](#molecules-24-01741-sch005){ref-type="scheme"}, [Scheme 6](#molecules-24-01741-sch006){ref-type="scheme"} and [Scheme 7](#molecules-24-01741-sch007){ref-type="scheme"}). Such reactions were carried out in dioxane in the presence of triethylamine to give thiazole derivatives **19a**--**f**, **21a**,**b**, **24** and **25**. The structure of all these compounds has been verified through their spectral data, elemental analysis and conformational analysis. [Figure 3](#molecules-24-01741-f003){ref-type="fig"} shows the fragmentation pattern for product **19b**. ^1^H NMR of compound **24** revealed all remarkable signals for aliphatic, aromatic and three NH protons as shown in the Experimental section. Moreover, the data from their IR spectra, which revealed the disappearance of C=O absorption bands and the existence of NH and C=N groups, proved the formation of these compounds **19a**--**f**, **21a**,**b**, **24** and **25**.

2.2. Conformational Study {#sec2dot2-molecules-24-01741}
-------------------------

All synthesized conformers as well as tautomers, were structurally investigated ([Figure S1](#app1-molecules-24-01741){ref-type="app"}), to confirm the proposed reaction mechanism. The reaction mechanism was already established mainly based on spectroscopic tools. The comparative view for conformer couples such as **6A** and **6B**; **7A** and **7B**; **8A** and **8B**; **12A** and **12B**; **17A** and **17B**, may confirm all reactions-pathways. The best discrimination among each couple confirms the mechanisms proposed in all the synthesis schemes. Firstly, their formation energies ([Table 1](#molecules-24-01741-t001){ref-type="table"}) point to their relative stability, which controls the reaction trends. As we know, the less the energy of formation (E, a. u.), the more stable the conformer. This appeared excellently for tautomers **A** not **B**. Secondly, the recorded energy gaps (∆E = E~LUMO~ − E~HOMO~), reflect the comparative stability that is consistent with the suggested conformers (**A** compounds). With respect to tautomers **3A** and **3B**, we considered the reaction-determining step of [Scheme 2](#molecules-24-01741-sch002){ref-type="scheme"}, and a remarkable stability was recorded for the **3A** tautomer. Also, regarding the two tautomers, the charge on the N(6) atom was −0.51307 or −0.338355, respectively. The two values indicate the highly nucleophilic nature of the nitrogen atom in compound **3A**. This agrees excellently with the previously suggested reaction pathway. Another additional proof was obtained from their electrostatic maps ([Figure 4](#molecules-24-01741-f004){ref-type="fig"}), which exhibited a broad electron cloud over **3A** (−6.935 × 10^−2^) but not the **3B** tautomer (−5.868 × 10^−2^). Such an observation suggests the superiority of **3A** tautomer over the **3B** one. Regarding intermediate **16**, the one in the reaction pathway in [Scheme 4](#molecules-24-01741-sch004){ref-type="scheme"}, its electrostatic map displays a broad electron cloud (−7.182 × 10^−2^) over the whole molecule. Also, the charge on N(18) (which is adjacent to the carbonyl group) was −0.782807, while the charge on N (14) was −0.580283, which points to the high nucleophilicity of the N(18) atom, which was already proposed in the reaction mechanism.

HOMO and LUMO frontier images were extracted and displayed ([Figures S2 and S3](#app1-molecules-24-01741){ref-type="app"}). The HOMO mainly appeared distributed over the whole molecule in a good way, especially for the **A** conformers, while, the LUMO mainly appeared condensed in a defined part in the compound. This is somewhat logical, that the two orbitals consider the counterparts in the compounds. Essential physical parameters were calculated for all optimized conformers, to gain some insight into their general characteristics. Electronegativity (*χ*), chemical potential (*μ*), global hardness (*η*), global softness (*S*), global electrophilicity index (*ω*) and absolute softness (σ), were the calculated parameters ([Table 1](#molecules-24-01741-t001){ref-type="table"}). The differentiation between all tested compounds allows us to make the following remarks; (i) the values of electrophilicity index (*ω*), reflect significant toxicity for most of the tested compounds, especially of **19**, **21**, **24** and **25**. (ii) The global hardness (*η*) and absolute softness (σ) values, clarify the high degree of softness for compounds **13**, **19**, **21** and **24** \[[@B29-molecules-24-01741],[@B30-molecules-24-01741],[@B31-molecules-24-01741],[@B32-molecules-24-01741]\], which should led to different biological activity.

2.3. Molecular Docking Study {#sec2dot3-molecules-24-01741}
----------------------------

This study aimed to provide a good simulation of what happens inside infected cells after treatment with the suggested inhibitors. Implementing the MOE module, the docking process was executed between **14**, **17a**, **19f** and **24** conformers and 3k4p, 1ydo and 1ecl PDB co-crystals of *Aspergillus niger*, *Bacillis subtilis* and *Escherichia coli*, respectively \[[@B33-molecules-24-01741]\]. Fundamental data was exported ([Table 2](#molecules-24-01741-t002){ref-type="table"}) and docking complexes images (interaction and surface maps), are presented as well in [Figure 5](#molecules-24-01741-f005){ref-type="fig"} and [Figure S4](#app1-molecules-24-01741){ref-type="app"}. [Table 2](#molecules-24-01741-t002){ref-type="table"} includes ligand types (centers of H- interaction), and protein receptors which interact with the ligands. Types of binding inside complexes, the length of H- bonding as well as energies calculated for docking complexes are also included.

The underlying mechanism of action was suggested by all docking processes, which varied from the best interaction to others with moderate binding, based on the following remarks;. (i) The energy value scores (S) appear in the −5.8156 to −7.0064 and −4.3294 to −5.3916 ranges, which represent the best to moderate interactions, respectively. (ii) The ligation mode was mainly focused on, S, N, 5-ring and 6-ring sites. (iii) The main binding receptor-backbones were lysine, asparagine, glutamate, alanine, serine and tryptophan. (iv) The interactions appeared to covering all possible types, such as π-H, π-π, H-donor and H-acceptor. (v) From all the previous remarks the best inhibition may be expected for **17a**, **24** and **19f** against the 1ydo protein of *Bacillis subtilis* bacteria \[[@B34-molecules-24-01741],[@B35-molecules-24-01741]\]. The displayed images of docking complexes ([Figure 5](#molecules-24-01741-f005){ref-type="fig"} and [Figure S3](#app1-molecules-24-01741){ref-type="app"}), especially with the interacting image (A), clarify the formerly concluded data. Regarding the surface maps (B images), which were built over line dummies without isolating the receptor atoms, they lead to a good view of the electrostatic interactions inside the docking complexes. Good inhibition is concluded with some conformers, which exhibit high occupancy of the inside surface grooves that point to a best blocking of amino acid active sites.

2.4. Biological Activity {#sec2dot4-molecules-24-01741}
------------------------

### Antimicrobial Activity

The antimicrobial activity was assayed for the starting α-bromoketone derivative **2** and the seventeen synthetic derivatives **6**--**8**, **12**--**14**, **17a**,**b**, **19a**, **19c**--**f**, **21a**,**b**, **24**, and **25** against two fungal species, and four Gram-positive as well as four Gram-negative bacteria, as illustrated in [Table 3](#molecules-24-01741-t003){ref-type="table"}. The activity was reported by measuring the diameter of the inhibition zone (IZD) in mm ± standard deviation. While determining the antimicrobial activity, amphotericin B, ampicillin, and gentamicin were used as reference compounds for fungi, Gram-positive bacteria, and Gram-negative bacteria, respectively.

It is easy to note that the starting α-bromoketone derivative **2** showed less activity than the the used antifungal and antibacterial standards against most of the tested fungi and bacteria. The activity of the thiazole ring was affected by the conversion of the α-bromoketone group to heterocyclic rings at position 5. The presence of an imidazotetrazole ring at position-5 of the thiazole ring, enhanced the activity of compound **12** (IZ = 23.3 µg/mL) to a level similar to that of amphotercin B against *Aspergillus niger*, whereas, upon insertion of imidazotriazole, thiazolopyrimidine, thiazole rings in the same position-5, a favorable activity was recorded for compounds **14**, **17a**, **19a**, **19c**--**f**, **21a** and **24** that exhibited higher activity than the standard drug toward *Aspergillus niger* ([Table 4](#molecules-24-01741-t004){ref-type="table"}, [Table 5](#molecules-24-01741-t005){ref-type="table"} and [Table 6](#molecules-24-01741-t006){ref-type="table"}). Investigating the product activity results recorded against Gram positive bacteria (*Staphylococcus aureus)*, three derivatives **14**, **19a** and **21a** are more potent than the reference drug (ampicillin), but only derivative **14** exceed the activity of the standard against *Staphylococcus epidermidis.* Observing Gram negative bacteria, six derivatives **17a**,**b**, **19a**,**e**,**f**, **24** are more potent than the reference drug, as depicted in [Table 4](#molecules-24-01741-t004){ref-type="table"}, [Table 5](#molecules-24-01741-t005){ref-type="table"} and [Table 6](#molecules-24-01741-t006){ref-type="table"}. In contrast to these results, we found that none of the investigated derivatives showed aany activity against Gram-positive *Streptococcus pyogenes* and Gram-negative *Pseudomonas aeruginosa*.

[Table 7](#molecules-24-01741-t007){ref-type="table"} presents the minimum inhibition concentration (MIC) values for some selected examples **7**, **13**, **17a**,**b**, **19c**, and **21b** that showed significant inhibition zones. The results revealed that most of these compounds displayed promising activity against *Aspergillus niger,* whereas, only compound **17a** showed MIC similar to Amphotericin B against *Geotricum candidum*. Focusing on the results of G (^+^) bacteria and G (^−^) bacteria*,* the most active derivative is **17a**. Moreover, compounds **7** and **13** showed high reactivity toward the bacterium *Salmonella typhimurium* (MIC = 0.49 μg/mL). Finally, from the inhibition zone and MIC investigations of the tested compounds, we found that the insertion of a heterocyclic system at position-5 of the thiazole ring, improved the antimicrobial activity. Also, with the presence of more than one thiazole ring in the system, promising activity concluded to be more than that of the reference antibiotics used was observed.

3. Experimental Section {#sec3-molecules-24-01741}
=======================

3.1. General Experimental Procedures {#sec3dot1-molecules-24-01741}
------------------------------------

All melting points were measured on a Electrothermal IA 9000 series digital melting point apparatus (Bibby Scientific Limited. Beacon Road, Stone, Staffordshire, UK). IR spectral analyses were recorded on a FT-IR-4100 spectrophotometer (400--4000 cm^−1^, JASCO, Easton, MD 21601, United States). ^1^H and ^13^C-NMR spectral analysis were obtained on a Bruker 400 MHz instrument (JEOL, Tokyo, Japan). Mass spectral analysis was obtained at 70 eV on Shimadzu GCMS-QP 1000 EX mass spectrometer (Tokyo, Japan) at a heating rate 40 °C/min. The elemental analysis was carried out using a 2400 CHN Elemental Analyzer (Perkin-Elmer, Inc. 940 Winter Street Waltham, MA, USA) instrument. The biological evaluation of the products was carried out at the Regional Center of Mycology and Biotechnology, Al-Azhar University, Cairo, Egypt. Theoretical calculations were performed using Gaussian 09 and AutoDock Tools 4.2. 2-Bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one (**2**) was synthesized as previously reported \[[@B25-molecules-24-01741]\].

3.2. Reaction of Heterocyclic Amines ***3***, ***4***, ***9***--***11*** and 2-Aminothioplenol (***5***) with 2-Bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one (***2***) {#sec3dot2-molecules-24-01741}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A mixture of equimolar quantities of *2-bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one* (**2**, 1.25 gm, 5 mmol) and heterocyclic amines **3**, **4**, **9**--**11** or 2-aminothioplenol **5** (5 mmol) in ethanol (30 mL) was refluxed for 10 h (the progress of the reactions was monitored by TLC). After the reaction was complete, the reaction mixture was filtered, the filtrate washed with methanol, and crystallized from a suitable solvent to give derivatives **6**, **7**, **12**--**14** and **8**, respectively.

### 3.2.1. 5-(Imidazo\[2,1-*b*\]thiazol-6-yl)-*N*,4-dimethylthiazol-2-amine (**6**) {#sec3dot2dot1-molecules-24-01741}

Yellow solid, (78% yield), mp 243--244 °C; (EtOH); IR (KBr) ν~max~ 3417 (NH), 3038 (sp^2^ C-H), 2997 (sp^3^ C-H), 1634 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.45 (s, 3H, CH~3~), 3.56 (s, 3H, CH~3~), 7.37 (d, *J* = 3.6 Hz, 1H, thiazole-H), 7.94 (d, *J* = 3.6 Hz, 1H, thiazole-H), 8.20 (s, 1H, imidazole-H), 9.60 (s, 1H, NH); MS *m*/*z* (%) 250 (M^+^, 26), 239 (53), 234 (47), 224 (89), 220 (16), 206 (62), 191 (45), 188 (57), 183 (100), 150 (30), 119 (34), 91 (33), 65 (42), 48 (54). Anal. Calcd. for C~10~H~10~N~4~S~2~ (250.34): C, 47.98; H, 4.03; N, 22.38. Found: C, 48.05; H, 3.89; N, 22.24%.

### 3.2.2. 5-(Benzo\[*d*\]imidazo\[2,1-*b*\]thiazol-2-yl)-*N*,4-dimethylthiazol-2-amine (**7**) {#sec3dot2dot2-molecules-24-01741}

Yellow solid, (83% yield), mp 265--266 °C; (EtOH); IR (KBr) ν~max~ 3238 (NH), 3047 (sp^2^ C-H), 2987 (sp^3^ C-H), 1623 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.59 (s, 3H, CH~3~), 3.56 (s, 3H, CH~3~), 7.40 (t, *J* = 7 Hz, 1H, Ar-H), 7.54 (t, *J* = 7 Hz, 1H, Ar-H), 8.01 (d, *J* = 7.7 Hz, 1H, Ar-H), 8.09 (d, *J* = 7.7 Hz, 1H, Ar-H), 8.76 (s, 1H, imidazole-H), 9.62 (s, 1H, NH); MS *m*/*z* (%) 300 (M^+^, 34), 285 (22), 270 (29), 254 (40), 175 (26), 153 (27), 147 (23), 150 (28), 138 (71), 129 (29), 77 (17). Anal. Calcd. for C~14~H~12~N~4~S~2~ (300.40): C, 55.98; H, 4.03; N, 18.65. Found: C, 55.87; H, 3.87; N, 18.58%.

### 3.2.3. 5-(4*H*-Benzo\[*b*\]\[1,4\]thiazin-3-yl)-*N*,4-dimethylthiazol-2-amine (**8**) {#sec3dot2dot3-molecules-24-01741}

Yellow solid, (88% yield), mp 110--112 °C; (EtOH/Dioxane); IR (KBr) ν~max~ 3374, 3293 (2NH), 3059 (sp^2^ C-H), 2926 (sp^3^ C-H), 1612 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.51 (s, 3H, CH~3~), 2.89 (s, 3H, CH~3~), 5.45 (s, 1H, benzothiazine-H), 6.42 (t, *J* = 7 Hz, 1H, Ar-H), 6.73 (d, *J* = 7 Hz, 1H, Ar-H), 7.01 (d, *J* = 7 Hz, 1H, Ar-H), 7.07 (t, *J* = 7 Hz, 1H, Ar-H), 7.4 (s, 1H, NH), 9.07 (s, 1H, NH); MS *m*/*z* (%) 275 (M^+^, 13), 272 (100), 256 (7), 166 (10), 154 (3), 152 (17), 147 (4), 139 (86), 127 (7), 113 (37), 102 (23), 91 (31), 83 (72), 76 (17). Anal. Calcd. for C~13~H~13~N~3~S~2~ (275.39): C, 56.70; H, 4.76; N, 15.26. Found: C, 56.85; H, 4.58; N, 15.17%.

### 3.2.4. 5-(4*H*-Imidazo\[1,2-*d*\]tetrazol-5-yl)-*N*,4-dimethylthiazol-2-amine (**12**) {#sec3dot2dot4-molecules-24-01741}

Yellow solid, (76% yield), mp 155--157 °C; (EtOH); IR (KBr) ν~max~ 3428, 3203 (2NH), 3106, 2924 (sp^3^ C-H), 1646, 1599 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.51 (s, 3H, CH~3~), 2.89 (s, 3H, CH~3~), 6.92 (s, 1H, NH), 7.03 (s, 1H, NH), 8.85 (s, 1H, imidazole-H); MS *m*/*z* (%) 235 (M^+^, 25), 220 (16), 210 (55), 192 (24), 191 (33), 189 (38), 170 (23), 123 (32), 106 (24), 103 (26), 96 (34), 82 (20), 64 (100). Anal. Calcd. for C~8~H~9~N~7~S (235.27): C, 40.84; H, 3.86; N, 41.68. Found: C, 41.10; H, 3.65; N, 41.59%.

### 3.2.5. 5-(1*H*-Benzo\[*d*\]imidazo\[1,2-*a*\]imidazol-2-yl)-*N*,4-dimethylthiazol-2-amine (**13**) {#sec3dot2dot5-molecules-24-01741}

Yellow solid, (65% yield), mp 140--142 °C; (EtOH/Dioxane); IR (KBr) ν~max~ 3438, 3165 (2NH), 3094 (sp^2^ C-H), 2991 (sp^3^ C-H), 1649 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.25 (s, 3H, CH~3~), 2.85 (s, 3H, CH~3~), 7.12 (d, *J* = 7 Hz, 1H, Ar-H), 7.24 (d, *J* = 7 Hz, 1H, Ar-H), 8.0--8.21 (m, 2H, Ar-H), 8.29 (s, 1H, imidazole-H), 10.44 (s, 1H, NH), 10.58 (s, 1H, NH); MS *m*/*z* (%) 283 (M^+^, 22), 264 (41), 245 (56), 238 (17), 230 (49), 207 (100), 181 (66), 167 (41), 137 (83), 124 (22), 115 (42), 98 (62), 67 (45). Anal. Calcd. for C~14~H~13~N~5~S (283.35): C, 59.34; H, 4.62; N, 24.72. Found: C, 59.17; H, 4.55; N, 24.60%.

### 3.2.6. 5-(4*H*-Imidazo\[1,2-*b*\]\[1,2,4\]triazol-5-yl)-*N*,4-dimethylthiazol-2-amine (**14**) {#sec3dot2dot6-molecules-24-01741}

Yellow crystals, (91% yield), mp 245--146 °C; (EtOH); IR (KBr) ν~max~ 3436, 3124(2NH), 2978 (sp^3^ C-H), 1629 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.41 (s, 3H, CH~3~), 3.03 (s, 3H, CH~3~), 6.75 (s, 1H, NH), 6.85 (s, 1H, NH), 9.55 (s, 2H, 2C-H); MS *m*/*z* (%) 234 (M^+^, 21), 224 (7), 221 (15), 187 (5), 166 (12), 153 (5), 145 (25), 127 (14), 118 (28), 107 (4), 84 (11), 73 (28), 67 (6), 65 (54), 63 (100). Anal. Calcd. for C~9~H~10~N~6~S (234.28): C, 46.14; H, 4.30; N, 35.87. Found: C, 46.25; H, 4.29; N, 35.75%.

3.3. Reaction of 2-Bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one (***2***) with Pyrimidinethione Derivatives ***15a**,**b** and thiosemicarbazones **18a**--**f**, **20a**,**b 22**, or **23*** {#sec3dot3-molecules-24-01741}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To a stirred hot solution of pyrimidinethione derivatives **15a** or **15b** or thiosemicarbazone derivatives **18a**--**f**, **20a**,**b 22**, or **23** (5 mmole) in dioxane (30 mL) was added 2-bromo-1-(4-methyl-2-(methylamino)thiazol-5-yl)ethan-1-one (**2**, 1.25 g, 5 mmol) and triethylamine (0.7 mL) then the reaction mixture was refluxed for 6 h. After cooling, the formed solid product was collected by filtration and washed with aqueous ethanol to dissolve any triethylamine hydrochloride crystals, dried and crystallized from ethanol/dioxane to give thiazolopyrimidines **17a**,**b** or hydrazine-thiazole derivatives **19a**--**f**, **21a**,**b**, **24** and **25**.

### 3.3.1. 3-(4-Methyl-2-(methylamino)thiazol-5-yl)-7-phenyl-5*H*-thiazolo\[3,2-*a*\]pyrimidin-5-one (**17a**) {#sec3dot3dot1-molecules-24-01741}

Yellow solid, (81% yield), mp 200--201 °C; IR (KBr) ν~max~ 3430 (NH), 2926 (sp^3^ C-H), 1653 (C=O), 1564 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.51 (s, 3H, CH~3~), 3.30 (s, 3H, CH~3~), 4.44 (s, 2H, CH~2~), 6.69 (s, 1H, pyrimidine-H), 7.36--7.95 (m, 5H, Ar-H); ^13^C-NMR (DMSO-*d*~6~) *δ* 18.9 (CH~3~), 30.1 (CH~2~), 34.0 (N-CH~3~), 110.9, 112.0, 114.3, 119.8, 125.5, 127.32, 129.6, 131.9, 132.6, 145.7, 147.6, 166.7 (C=O) ppm; MS *m*/*z* (%) 354 (M^+^, 40), 338 (28), 331 (40), 327 (30), 311 (41), 269 (44), 258 (69), 201 (30), 173 (43), 155 (56), 111 (83), 86 (47), 60 (100). Anal. Calcd. for C~17~H~14~N~4~OS~2~ (354.45): C, 57.61; H, 3.98; N, 15.81. Found: C, 57.73; H, 3.76; N, 15.72%.

### 3.3.2. 7-Methyl-3-(4-methyl-2-(methylamino)thiazol-5-yl)-5*H*-thiazolo\[3,2-*a*\]pyrimidin-5-one (**17b**) {#sec3dot3dot2-molecules-24-01741}

Dark orange solid, (92% yield), mp 259--260 °C; IR (KBr) ν~max~ 3430 (NH), 2928 (sp^3^ C-H), 1636 (C=O), 1560 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.07 (s, 3H, CH~3~), 2.51 (s, 3H, CH~3~), 3.37 (s, 3H, CH~3~), 5.68 (s, 2H, pyrimidine-H and thiazole-H), 12.24 (s, 1H, NH). MS *m*/*z* (%) 292 (M^+^, 100), 284 (59), 277 (23), 265 (21), 256 (63), 246 (32), 231 (25), 202 (44), 163 (25), 139 (16), 127 (40), 108 (53), 87 (35), 82 (25). Anal. Calcd. for C~12~H~12~N~4~OS~2~ (292.38): C, 49.30; H, 4.14; N, 19.16. Found: C, 49.45; H, 4.05; N, 19.02%.

### 3.3.3. N,4′-dimethyl-2-(2-(1-phenylethylidene)hydrazineyl)-\[4,5′-bithiazol\]-2′-amine (**19a**) {#sec3dot3dot3-molecules-24-01741}

Green solid, (77% yield), mp 235--237 °C; IR (KBr) ν~max~ br. 3419 (2NH), 2929 (sp^3^ C-H), 1554 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.31 (s, 3H, CH~3~), 2.51 (s, 3H, CH~3~), 2.89 (s, 3H, CH~3~), 7.39--8.27 (m, 7H, Ar-H, thiazole-H, NH), 10.22 (s, 1H, NH); MS *m*/*z* (%) 343 (M^+^, 14), 334 (14), 303 (17), 282 (30), 218 (20), 163 (10), 127 (100), 93 (61), 91 (49), 85 (12). Anal. Calcd. for C~16~H~17~N~5~S~2~ (343.47): C, 55.95; H, 4.99; N, 20.39. Found: C, 56.14; H, 4.80; N, 20.27%.

### 3.3.4. 2-(2-(1-(4-Chlorophenyl)ethylidene)hydrazineyl)-*N*,4′-dimethyl-\[4,5′-bithiazol\]-2′-amine (**19b**) {#sec3dot3dot4-molecules-24-01741}

Green solid, (68% yield), mp 226--228 °C; IR (KBr) ν~max~ br. 3423 (2NH), 2925 (sp^3^ C-H),1552 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.29 (s, 3H, CH~3~), 2.33 (s, 3H, CH~3~), 3.37 (s, 3H, CH~3~), 7.42--7.98 (m, 6H, Ar-H, thiazole-H, NH), 10.26 (s, 1H, NH); MS *m*/*z* (%) 379 (M^+^+2, 12), 378 (M^+^+1, 4), 377 (M^+^, 38), 364 (28), 346 (25), 337 (34), 328 (100), 265 (50), 251 (49), 239 (43), 225 (22), 216 (30), 188 (49), 128 (52), 83 (53). Anal. Calcd. for C~16~H~16~ClN~5~S~2~ (377.91): C, 50.85; H, 4.27; N, 18.53. Found: C, 51.02; H, 4.13; N, 18.44%.

### 3.3.5. 2-(2-(1-(4-Bromophenyl)ethylidene)hydrazineyl)-*N*,4′-dimethyl-\[4,5′-bithiazol\]-2′-amine (**19c**) {#sec3dot3dot5-molecules-24-01741}

Green solid, (64% yield), mp 220--222 °C; IR (KBr) ν~max~ br. 3416 (2NH), 2919 (sp^3^ C-H), 1552 cm-1; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.28 (s, 3H, CH~3~), 2.33 (s, 3H, CH~3~), 3.36 (s, 3H, CH~3~), 7.56--7.92 (m, 5H, Ar-H, thiazole-H), 8.31 (s, 1H, NH), 10.26 (s, 1H, NH); MS *m*/*z* (%) 422 (M^+^, 25), 406 (52), 390 (100), 371 (56), 347 (32), 325 (37), 302 (38), 270 (67), 238 (36), 111 (24), 72 (20). Anal. Calcd. for C~16~H~16~BrN~5~S~2~ (422.36): C, 45.50; H, 3.82; N, 16.58. Found: C, 45.75; H, 3.68; N, 16.46%.

### 3.3.6. 2-(2-(1-(4-Fluorophenyl)ethylidene)hydrazineyl)-*N*,4′-dimethyl-\[4,5′-bithiazol\]-2′-amine (**19d**) {#sec3dot3dot6-molecules-24-01741}

Green solid, (72% yield), mp 249--250 °C; IR (KBr) ν~max~ 3423, 3249 (2NH), 3161, 2936 (sp^3^ C-H), 1602, 1560 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.28 (s, 3H, CH~3~), 2.51 (s, 3H, CH~3~), 3.51 (s, 3H, CH~3~), 7.17--8.00 (m, 5H, Ar-H, thiazole-H), 8.24 (s, 1H, NH), 10.19 (s, 1H, NH); MS *m*/*z* (%) 361 (M^+^, 12), 338 (22), 299 (66), 273 (45), 271 (100), 252 (16), 202 (16), 189 (15), 136 (39). Anal. Calcd. for C~16~H~16~FN~5~S~2~ (361.46): C, 53.17; H, 4.46; N, 19.38. Found: C, 53.24; H, 4.31; N, 19.29%.

### 3.3.7. *N*,4′-Dimethyl-2-(2-(1-(*p*-tolyl)ethylidene)hydrazineyl)-\[4,5′-bithiazol\]-2′-amine (**19e**) {#sec3dot3dot7-molecules-24-01741}

Green solid, (68% yield), mp 229--230 °C; IR (KBr) ν~max~ br. 3411 (2NH), 2919 (sp^3^ C-H), 1552 cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.25 (s, 3H, CH~3~), 2.35 (s, 3H, CH~3~), 2.50 (s, 3H, CH~3~), 3.26 (s, 3H, CH~3~), 6.94 (d, *J* = 7 Hz, 2H, Ar-H), 7.07 (s, 1H, thiazole-H), 7.76 (d, *J* = 7 Hz, 2H, Ar-H), 8.50 (s, 1H, NH), 10.21 (s, 1H, NH); MS *m*/*z* (%) 357 (M^+^, 35), 346 (53), 324 (100), 298 (60), 270 (45), 229 (34), 174 (68), 145 (44), 135 (81), 115 (50), 65 (56). Anal. Calcd. for C~17~H~19~N~5~S~2~ (357.49): C, 57.12; H, 5.36; N, 19.59. Found: C, 57.30; H, 5.33; N, 19.46%.

### 3.3.8. 2-(2-(1-(4-Methoxyphenyl)ethylidene)hydrazineyl)-*N*,4′-dimethyl-\[4,5′-bithiazol\]-2′-amine (**19f**) {#sec3dot3dot8-molecules-24-01741}

Green solid, (75% yield), mp 195--197 °C; IR (KBr) ν~max~ 3386, 3265 (2NH), 2926 (sp^3^ C-H), 1597 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.00 (s, 3H, CH~3~), 2.51 (s, 3H, CH~3~), 2.80 (s, 3H, CH~3~), 3.86 (s, 3H, OCH~3~), 7.30 (s, 1H, thiazole-H), 7.44 (d, *J* = 7 Hz, 2H, Ar-H), 7.57 (d, *J* = 7 Hz, 2H, Ar-H), 8.29 (s, 1H, NH), 10.39 (s, 1H, NH); MS *m*/*z* (%) 373 (M^+^, 24), 369 (52), 346 (100), 332 (55), 284 (24), 270 (63), 250 (34), 177 (36), 123 (37), 111 (63), 76 (38). Anal. Calcd. for C~17~H~19~N~5~OS~2~ (373.49): C, 54.67; H, 5.13; N, 18.75. Found: C, 54.76; H, 5.24; N, 18.65%.

### 3.3.9. 2-(2-(1-(5-Imino-4-(*p*-tolyl)-4,5-dihydro-1,3,4-thiadiazol-2-yl)ethylidene)hydrazineyl)-N,4′-dimethyl-\[4,5′-bithiazol\]-2′-amine (**21a**) {#sec3dot3dot9-molecules-24-01741}

Green solid, (68% yield), mp 270--271 °C; IR (KBr) ν~max~ br. 3423 (3NH), 2927 (sp^3^ C-H), 1590 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.34 (s, 3H, CH~3~), 2.39 (s, 3H, CH~3~), 2.51 (s, 3H, CH~3~), 3.35 (s, 3H, CH~3~), 6.69--8.08 (m, 6H, Ar-H, thiazole-H, NH), 9.39 (s, 1H, NH), 10.91 (s, 1H, NH); MS *m*/*z* (%) 456 (M^+^, 34), 420 (24), 367 (24), 267 (26), 249 (52), 200 (44), 139 (33), 104 (21), 85 (60), 76 (29). Anal. Calcd. for C~19~H~20~N~8~S~3~ (456.61): C, 49.98; H, 4.42; N, 24.54. Found: C, 50.11; H, 4.27; N, 24.35%.

### 3.3.10. 2-(2-(1-(4-(4-Chlorophenyl)-5-imino-4,5-dihydro-1,3,4-thiadiazol-2-yl)ethylidene)-hydrazineyl)-*N*,4′-dimethyl-\[4,5′-bithiazol\]-2′-amine (**21b**) {#sec3dot3dot10-molecules-24-01741}

Green solid, (65% yield), mp 278--280 °C; IR (KBr) ν~max~ br. 3425 (3NH), 2991 (sp^3^ C-H), 1621 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 1.92 (s, 3H, CH~3~), 2.41 (s, 3H, CH~3~), 2.68 (s, 3H, CH~3~), 7.50--8.11 (m, 6H, Ar-H, thiazole-H, NH), 8.66 (s, 1H, NH), 10.92 (s, 1H, NH); MS *m*/*z* (%) 479 (M^+^+2, 34), 477 (M^+^, 73), 461 (41), 382 (33), 313 (15), 222 (26), 202 (36), 111 (15), 108 (32), 96 (100). Anal. Calcd. for C~18~H~17~ClN~8~S~3~ (477.02): C, 45.32; H, 3.59; N, 23.49. Found: C, 45.43; H, 3.41; N, 23.28%.

### 3.3.11. 3-(2-(4′-Methyl-2′-(methylamino)-\[4,5′-bithiazol\]-2-yl)hydrazineylidene)indolin-2-one (**24**) {#sec3dot3dot11-molecules-24-01741}

Brown solid, (79% yield), mp 210--212 °C; IR (KBr) ν~max~ 3419, 3262 (3NH), 1650 (C=O), 1600 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.51 (s, 3H, CH~3~), 3.39 (s, 3H, CH~3~), 6.92 (d, *J* = 7.8 Hz, 1H, Ar-H), 7.07 (t, *J* = 7.45 Hz, 1H, Ar-H), 7.33 (t, *J* = 7.5 Hz, 1H, Ar-H), 7.65 (d, *J* = 7.44 Hz, 1H, Ar-H), 8.68 (s, 1H, thiazole-H), 9.03 (s, 1H, NH), 11.21 (s, 1H, NH), 12.48 (s, 1H. NH); MS *m*/*z* (%) 370 (M^+^, 29), 356 (50), 340 (32), 244 (45), 337 (50), 305 (40), 297 (63), 282 (25), 264 (58), 224 (32), 211 (44), 190 (100), 87 (44), 82 (19), 77 (32). Anal. Calcd. for C~16~H~14~N~6~OS~2~ (370.45): C, 51.88; H, 3.81; N, 22.69. Found: C, 52.02; H, 3.65; N, 22.53%.

### 3.3.12. 2,2′′-((1*H*-Indene-1,3(2*H*)-diylidene)bis(hydrazin-1-yl-2-ylidene))bis(*N*,4′-dimethyl-\[4,5′-bithiazol\]-2′-amine) (**25**) {#sec3dot3dot12-molecules-24-01741}

Brown solid, (72% yield), mp 216--217 °C; IR (KBr) ν~max~ 3415, 3240 (2NH), 2937 (sp^3^ C-H), 1575 (C=N) cm^−1^; ^1^H-NMR (DMSO-*d*~6~) *δ* 2.51 (s, 6H, 2CH~3~), 3.38 (s, 6H, 2CH~3~), 3.83 (s, 2H, CH~2~), 7.51--8.03 (m, 4H, Ar-H), 8.13(s, 2H, thiazole-H), 8.40 (s, 2H, 2NH), 10.02 (s, 2H, 2NH); MS *m*/*z* (%) 593 (M^+^+1, 11), 567 (14), 548 (23), 531 (20), 510 (14), 439 (20), 404 (20), 360 (100), 352 (15), 276 (31), 226 (11), 211 (13), 200 (58). Anal. Calcd. for C~25~H~24~N~10~S~4~ (592.78): C, 50.66; H, 4.08; N, 23.63. Found: C, 50.76; H, 4.14; N, 23.58%.

3.4. Antimicrobial Screening {#sec3dot4-molecules-24-01741}
----------------------------

The starting α-bromoketone derivative **2** and the new thiazole compounds **6**--**8**, **12**--**14**, **17a**,**b**, **19a**, **19c**--**f**, **21a**,**b**, **24** and **25** were assayed in vitro for their antimicrobial activity against two fungal species, namely *Aspergillus niger, Geotricum candidum*, four Gram-positive bacteria*: Staphylococcus aureus, Staphylococcus epidermidis, Bacillis subtilis, Streptococcus pyogenes,* and four Gram-negative bacteria: *Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Salmonella typhimurium* using the known the agar diffusion procedure \[[@B36-molecules-24-01741]\]. Firstly, the microorganisms were screened separately versus the activity of the solutions of each compound (30 μg/mL) and using the IZD diameter of the mm/mg sample as a measure of antimicrobial activity. The microorganisms were spread uniformly using a sterile cotton swab on a fresh Petri dish filled with agar and nutritient agar. One hundred μL of each sample was added to each well (10 mm diameter holes cut into the agar gel, 20 mm apart from each other). Petri dishes were incubated at 36 °C for bacteria and at 28 °C for fungus and inhibition zones were measured after 24 h of incubation. Inhibition of growth of bacteria and fungi was measured as IZD in mm. Each test was repeated three times and the average value is recorded. The fungicide amphotericin and gentamicin and ampicillin were used as a reference to evaluate the efficacy of the tested compounds under the same conditions.

3.5. Conformational Study {#sec3dot5-molecules-24-01741}
-------------------------

The synthesis pathways were also confirmed based on structural configuration studies which were performed using the Gaussian 09 software \[[@B37-molecules-24-01741]\]. To determine the most stable conformers (in gas phase), the DFT method was applied as B3LYP-FC, by using the 3-21G or 6-31G basis sets. Two significant files were extracted (log and chk), which feed the study of the essential parameters, for confirmation. All optimized conformers were visualized using the Gauss-View program screen \[[@B38-molecules-24-01741]\], to obtain frontier energy gaps and electrostatic potential maps. Other physical parameters were computed by using standard equations \[[@B39-molecules-24-01741],[@B40-molecules-24-01741]\].

3.6. Molecular Docking Study {#sec3dot6-molecules-24-01741}
----------------------------

Through the MOE module (v. 2015), the molecular docking process was implemented forselected compounds against three microorganisms. Regarding the tested inhibitors, the selection aimd to cover all the various synthesis pathways, to give a broad view about their interactions with pathogen proteins. Regarding the selected pathogens, *Aspergillus niger*, *Bacillis subtilis* and *Escherichia coli*, which cover fungi and bacteria, were selected, which will simulate the intended screening in vitro study. 3k4p, 1ydo and 1ecl, were the co-crystalline structures as PDB files, which are attributed to the reported microorganisms, respectively. This introductory study may strengthen the experimental screening, which will be displayed later. Firstly the docked synthesis must be configured by the addition of hydrogen atoms, after removing water molecules around the skeletons. Then the potential energy must be fixed after displaying the atomic charges and other important parameters adapted by the MMFF94x force field. After that, the oriented compounds must be saved as MDB format, to be ready for the docking process. The PDB files of co-crystallized proteins are configured by addition of hydrogen, choosing the receptor and generating the α-site spheres in the site finder \[[@B41-molecules-24-01741]\]. The docking inhibitors will attack the protein-surfaces in its interior-grooves, after 30 trials, till the most stable docking complexes are reached. The scoring energies, which were the mean values of trials using the London dG scoring function, were upgraded by two unrelated-refinements by the triangular Matcher methods. The interacting complexes as well as electrostatic maps for the interacting surfaces were extracted, in addition to essential interaction parameters. The grade of inhibition was judged based on the extracted parameters such as ligand, receptor backbones (amino acids), interaction type, bond lengths, internal and scoring energies. The bond lengths must be verified, are were limited to ≤ 3.5 Å

4. Conclusions {#sec4-molecules-24-01741}
==============

A main and growing health problem around the world is microbial resistance to existing treatments. Several studies have been conducted aiming to synthesize thiazole derivatives with excellent antimicrobial activity. In this context we focused on the synthesis for a new series of thiazole derivatives with varying substituents at position-5. The atomic assembly and the mechanistic pathway for all products have been investigated and proved based on our spectral and conformational studies. Antimicrobial results for the starting material (α-bromoketone) and the products indicated that the antimicrobial activity of some new synthetic products is more efficient than that of the starting material itself. This activity of the derivatives was somewhat improved to exceed the activity of standard drugs.
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Best docking interaction (**A**) and surfaces maps (**B**) of selected compounds.
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###### 

Calculated physical parameters for all suggested conformers.

  Conformers         E~H~ (eV)   E~L~ (eV)   E~H~ − E~L~   E~L~ − E~H~   *x*(eV)       µ(eV)         η(eV)         S(eV-1)       ω(eV)         σ(eV)         D~(Debye)~   E ~(a.\ u.)~
  ------------------ ----------- ----------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------ --------------
  **3A**             −0.20464    −0.00446    −0.2002       0.20018       0.10455       −0.10455      0.10009       0.050045      0.054604      9.991008093   2.4276       −621.17858
  **3B**             −0.20794    −0.01183    −0.1961       0.19611       \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   2.7935       −621.14667
  **6A**             −0.2024     −0.07871    −0.1237       0.12369       0.140555      −0.14056      0.061845      0.030923      0.15972       16.1694559    6.0085       −1394.9439
  **6B**             −0.17951    −0.07617    −0.1033       0.10334       \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   10.9130      −1394.4678
  **7A**             −0.19955    −0.0716     −0.128        0.12795       0.135575      −0.13558      0.063975      0.031988      0.143654      15.6311059    6.0625       −1547.7641
  **7B**             −0.14724    −0.09765    −0.0496       0.04959       \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   13.5781      −1547.1272
  **8A**             −0.1861     −0.06861    −0.1175       0.11749       0.127355      −0.12736      0.058745      0.029373      0.138048      17.02272534   7.8499       −1456.1575
  **8B**             −0.18661    −0.0561     −0.1305       0.13051       \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   6.2621       −1456.0837
  **12A**            −0.20807    −0.08663    −0.1214       0.12144       0.14735       −0.14735      0.06072       0.03036       0.178788      16.46903821   12.6129      −1085.6105
  **12B**            −0.21277    −0.10635    −0.1064       0.10642       \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   10.4034      −1085.4218
  **13**             −0.19029    −0.09108    −0.0992       0.09921       0.140685      −0.14069      0.049605      0.024803      0.199499      20.15925814   10.1242      −1206.5564
  **14**             −0.2007     −0.06744    −0.1333       0.13326       0.13407       −0.13407      0.06663       0.033315      0.134885      15.00825454   8.2866       −1069.7172
  **16**             −0.21735    −0.06425    −0.1531       0.1531        0.1408        −0.1408       0.07655       0.038275      0.129488      13.06335728   5.5798       −1813.6492
  **17A (R = Ph)**   −0.19633    −0.06873    −0.1276       0.1276        0.13253       −0.13253      0.0638        0.0319        0.13765       15.67398119   3.9127       −1737.5001
  **17B (R = Ph)**   −0.16956    −0.10827    −0.0613       0.06129       \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   \-\-\-\-\--   15.6710      −1728.4984
  **19a**            −0.22389    −0.12297    −0.1009       0.10092       0.17343       −0.17343      0.05046       0.02523       0.298038      19.81767737   2.9358       −1679.9270
  **21 (X = H)**     −0.21284    −0.12465    −0.0882       0.08819       0.168745      −0.16875      0.044095      0.022048      0.322881      22.6783082    6.1375       −2315.6659
  **24**             −0.17775    −0.09774    −0.08         0.08001       0.137745      −0.13775      0.040005      0.020003      0.237141      24.99687539   2.8473       −1817.4536
  **25**             −0.25151    −0.01744    −0.2341       0.23407       0.134475      −0.13448      0.117035      0.058518      0.077257      8.544452514   6.9055       −3093.4323
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###### 

The energy score and binding data for all compounds against selected proteins.

  Compound   Protein     Ligand      Receptor     Interaction   Distance    E (Kcal/mol)   S (Energy Score)   
  ---------- ----------- ----------- ------------ ------------- ----------- -------------- ------------------ ---------
  **14**     3k4p        S 4         OG           SER           H-donor     3.75           −0.5               −5.1153
  99         \(A\)                                                                                            
  N 13       OG          SER         H-donor      3.09          −1.6                                          
  99         \(A\)                                                                                            
  5-ring     CB          THR         pi-H         4.41          −0.5                                          
  248        \(A\)                                                                                            
  1ydo       \-\-\-\--   \-\-\-\--   \-\-\-\--    \-\-\-\--     \-\-\-\--   −4.5481                           
  1ecl       N 13        O           HOH          H-donor       3.33        −1.7           −4.3294            
  744        \(A\)                                                                                            
  **17a**    3k4p        S 4         OE1          GLN           H-donor     3.18           −0.7               −5.2078
  13         \(B\)                                                                                            
  6-ring     CB          GLN         pi-H         4.00          −0.5                                          
  16         \(B\)                                                                                            
  6-ring     CA          CYS         pi-H         4.35          −0.8                                          
  17         \(B\)                                                                                            
  1ydo       5-ring      CB          LYS          pi-H          4.00        −1.1           −7.0064            
  297        \(B\)                                                                                            
  1ecl       \-\-\-\--   \-\-\-\--   \-\-\-\--    \-\-\-\--     \-\-\-\--   −4.9748                           
  **19f**    3k4p        S 1         OD1          ASN           H-donor     3.88           −1.4               −5.8156
  36         \(A\)                                                                                            
  N 6        OE2         GLU         H-donor      2.99          −4.6                                          
  43         \(A\)                                                                                            
  S 20       O           ALA         H-donor      3.43          −1.3                                          
  35         \(A\)                                                                                            
  N 22       O           SER         H-donor      3.01          −1.7                                          
  38         \(A\)                                                                                            
  5-ring     CA          SER         pi-H         4.10          −0.5                                          
  41         \(A\)                                                                                            
  1ydo       5-ring      5-ring      TRP          pi-pi         3.88        −0.0           −6.2008            
  55         \(A\)                                                                                            
  5-ring     6-ring      TRP         pi-pi        4.00          −0.0                                          
  55         \(A\)                                                                                            
  5-ring     6-ring      TRP         pi-pi        3.8           −0.0                                          
  55         \(A\)                                                                                            
  1ecl       S 20        OD2         ASP          H-donor       3.52        −2.9           −5.0501            
  62         \(A\)                                                                                            
  N 7        O           HOH         H-acceptor   3.03          −0.9                                          
  1030       \(A\)                                                                                            
  N 18       O           HOH         H-acceptor   3.60          −1.2                                          
  1039       \(A\)                                                                                            
  **24**     3k4p        N 7         OE1          GLU           H-donor     3.2            −0.7               −5.3916
  37         \(A\)                                                                                            
  N 11       O           GLU         H-donor      3.49          −0.7                                          
  37         \(A\)                                                                                            
  S 17       O           GLU         H-donor      4.21          −0.9                                          
  37         \(A\)                                                                                            
  5-ring     CG          PRO         pi-H         3.64          −0.8                                          
  409        \(A\)                                                                                            
  1ydo       5-ring      CB          LYS          pi-H          4.27        −0.5           −6.8467            
  297        \(B\)                                                                                            
  1ecl       S 22        OD2         ASP          H-donor       3.80        −3.3           −4.9736            
  506        \(A\)                                                                                            
  N 23       OD2         ASP         H-donor      3.05          −4.0                                          
  506        \(A\)                                                                                            
  O 13       NZ          LYS         H-acceptor   3.22          −5.1                                          
  302        \(A\)                                                                                            
  5-ring     O           HOH         pi-H         3.63          −1.2                                          
  661        \(A\)                                                                                            
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###### 

Preliminary anti-microbial activity for compounds **2**, **6**--**8**, **12**.

  Microorganism                      2             6                    7             8             12            ST. (30 µg/mL)
  ---------------------------------- ------------- -------------------- ------------- ------------- ------------- ----------------
  ***Fungi***                                      **Amphotericin B**                                             
  ***Aspergillus niger***            18.8 ± 0.63   19.3 ± 0.63          18.4 ± 1.20   19.2 ± 0.72   23.3 ± 0.72   23.3 ± 0.58
  ***Geotricum candidum***           19.3 ± 0.58   18.1 ± 0.58          16.3 ± 0.63   17.3 ± 0.72   22.3 ± 1.20   25.2 ± 0.72
  ***G(^+^) Bacteria***                            **Ampicillin**                                                 
  ***Staphylococcus aureus***        17.6 ± 0.85   19.3 ± 0.58          21.1 ± 0.63   13.5 ± 1.20   20.1 ± 0.58   23.7 ± 0.63
  ***Staphylococcus epidermidis***   18.1 ± 1.20   17.4 ± 0.58          20.7 ± 0.72   15.3 ± 0.44   17.6 ± 0.72   22.4 ± 0.3
  ***Bacillis subtilis***            18.3 ± 0.63   22.7 ± 1.20          20.1 ± 0.53   18.2 ± 0.58   24.3 ± 0.58   32.4 ± 1.20
  ***Streptococcus pyogenes***       NA            NA                   NA            NA            NA            24.5 ± 0.63
  ***G(^−^) Bacteria***                            **Gentamicin**                                                 
  ***Pseudomonas aeruginosa***       NA            NA                   NA            NA            NA            22.3 ± 0.58
  ***Escherichia coli***             20.2 ± 0.58   20.3 ± 0.63          19.3 ± 1.20   19.3 ± 0.63   23.7 ± 0.72   25.4 ± 1.20
  ***Klebsiella pneumoniae***        18.2 ± 1.20   18.2 ± 0.58          19.2 ± 1.20   16.3 ± 0.63   19.3 ± 0.63   22.6 ± 0.63
  ***Salmonella typhimurium***       17.5 ± 0.63   20.4 ± 0.72          18.4 ± 0.58   19.3 ± 0.58   21.6 ± 0.63   23.3 ± 0.58

![](molecules-24-01741-i002.jpg) The tested compound has activity similar to reference drug.
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###### 

Preliminary anti-microbial activity for compounds **13**, **14**, **17a**,**b** and **19a**.

  Microorganism                      13            14                   17a           17b           19a           ST. (30 µg/mL)
  ---------------------------------- ------------- -------------------- ------------- ------------- ------------- ----------------
  ***Fungi***                                      **Amphotericin B**                                             
  ***Aspergillus niger***            21.2 ± 1.20   25.4 ± 1.20          24.3 ± 1.20   23.1 ± 1.20   25.0 ± 0.72   23.3 ± 0.58
  ***Geotricum candidum***           19.3 ± 0.85   20.9 ± 0.72          24.2 ± 1.20   23.6 ± 1.20   23.6 ± 0.63   25.2 ± 0.72
  ***G (^+^)Bacteria***                            **Ampicillin**                                                 
  ***Staphylococcus aureus***        16.8 ± 0.63   24.3 ± 0.63          23.6 ± 0.63   22.4 ± 0.63   23.8 ± 0.72   23.7 ± 0.63
  ***Staphylococcus epidermidis***   15.2 ± 0.58   22.8 ± 0.58          22.4 ± 0.72   20.9 ± 0.72   21.9 ± 0.72   22.4 ± 0.3
  ***Bacillis subtilis***            20.6 ± 0.58   21.6 ± 0.53          27.2 ± 0.63   29.8 ± 0.63   25.2 ± 0.63   32.4 ± 1.20
  ***Streptococcus pyogenes***       NA            NA                   NA            NA            NA            24.5 ± 0.63
  ***G (^−^)Bacteria***                            **Gentamicin**                                                 
  ***Pseudomonas aeruginosa***       NA            NA                   NA            NA            NA            22.3 ± 0.58
  ***Escherichia coli***             19.8 ± 1.20   24.3 ± 1.20          26.7 ± 1.20   24.3 ± 1.20   26.9 ± 1.20   25.4 ± 1.20
  ***Klebsiella pneumoniae***        18.3 ± 0.53   22.2 ± 0.44          25.3 ± 1.20   22.2 ± 1.20   26.3 ± 1.20   22.6 ± 0.63
  ***Salmonella typhimurium***       20.1 ± 0.63   21.1 ± 0.72          26.3 ± 0.58   24.8 ± 0.58   22.2 ± 0.58   23.3 ± 0.58

![](molecules-24-01741-i001.jpg) The tested compound has activity exceed the reference drug.

![](molecules-24-01741-i002.jpg) The tested compound has activity similar to reference drug.
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###### 

Preliminary anti-microbial activity for compounds **19c**--**f** and **21a**.

  Microorganism                      19c           19d                  19e           19f           21a           ST. (30 µg/mL)
  ---------------------------------- ------------- -------------------- ------------- ------------- ------------- ----------------
  ***Fungi***                                      **Amphotericin B**                                             
  ***Aspergillus niger***            21.8 ± 0.43   25.2 ± 2.10          24.1 ± 0.58   26.3 ± 0.63   25.2 ± 2.10   23.3 ± 0.58
  ***Geotricum candidum***           21.4 ± 0.72   23.2 ± 2.10          20.5 ± 0.58   24.2 ± 0.63   23.2 ± 2.10   25.2 ± 0.72
  ***G (^+^) Bacteria***                           **Ampicillin**                                                 
  ***Staphylococcus aureus***        20.3 ± 0.43   22.1 ± 1.20          22.4 ± 0.63   22.7 ± 1.20   24.1 ± 1.20   23.7 ± 0.63
  ***Staphylococcus epidermidis***   18.6 ± 0.58   19.8 ± 0.67          20.9 ± 0.72   21.3 ± 0.58   19.8 ± 0.67   22.4 ± 0.3
  ***Bacillis subtilis***            22.4 ± 1.53   24.3 ± 0.58          23.8 ± 0.63   23.9 ± 0.72   26.3 ± 0.58   32.4 ± 1.20
  ***Streptococcus pyogenes***       NA            NA                   NA            NA            NA            24.5 ± 0.63
  ***G (^−^) Bacteria***                           **Gentamicin**                                                 
  ***Pseudomonas aeruginosa***       NA            NA                   NA            NA            NA            22.3 ± 0.58
  ***Escherichia coli***             23.3 ± 0.58   24.2 ± 0.58          24.3 ± 1.20   25.4 ± 1.20   24.2 ± 0.58   25.4 ± 1.20
  ***Klebsiella pneumoniae***        20.4 ± 0.53   21.3 ± 0.58          22.5 ± 1.20   23.1 ± 1.20   21.3 ± 0.58   22.6 ± 0.63
  ***Salmonella typhimurium***       22.6 ± 0.63   23.3 ± 1.20          26.3 ± 0.58   26.7 ± 0.72   23.3 ± 1.20   23.3 ± 0.58

![](molecules-24-01741-i001.jpg) The tested compound has activity exceed the reference drug.

![](molecules-24-01741-i002.jpg) The tested compound has activity similar to reference drug.
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###### 

Preliminary anti-microbial activity for compounds **21b**, **24** and **25**.

  Microorganism                      21b           24                   25            ST. (30 µg/mL)
  ---------------------------------- ------------- -------------------- ------------- ----------------
  ***Fungi***                                      **Amphotericin B**                 
  ***Aspergillus niger***            19.2 ± 0.72   26.3 ± 0.63          23.3 ± 0.72   23.3 ± 0.58
  ***Geotricum candidum***           16.3 ± 0.72   24.2 ± 0.63          21.4 ± 0.72   25.2 ± 0.72
  ***G(^+^) Bacteria***                            **Ampicillin**                     
  ***Staphylococcus aureus***        17.5 ± 1.20   22.7 ± 1.20          20.3 ± 0.43   23.7 ± 0.63
  ***Staphylococcus epidermidis***   21.3 ± 0.44   21.3 ± 0.58          19.8 ± 0.58   22.4 ± 0.3
  ***Bacillis subtilis***            18.2 ± 0.58   28.9 ± 0.72          25.4 ± 0.53   32.4 ± 1.20
  ***Streptococcus pyogenes***       NA            NA                   NA            24.5 ± 0.63
  ***G (^−^) Bacteria***                           **Gentamicin**                     
  ***Pseudomonas aeruginosa***       NA            NA                   NA            22.3 ± 0.58
  ***Escherichia coli***             20.3 ± 0.63   25.6 ± 1.20          24.3 ± 0.53   25.4 ± 1.20
  ***Klebsiella pneumoniae***        21.3 ± 0.63   23.8 ± 1.20          21.5 ± 0.53   22.6 ± 0.63
  ***Salmonella typhimurium***       19.9 ± 0.58   25.4 ± 0.72          22.6 ± 0.63   23.3 ± 0.58

![](molecules-24-01741-i001.jpg) The tested compound has activity exceed the reference drug.

![](molecules-24-01741-i002.jpg) The tested compound has activity similar to reference drug.
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###### 

Minimum inhibitory concentration of compounds **7**, **13**, **17a**,**b**, **19c** and **21b** (µg/mL).

  Microorganism                      7      13                   17a    17b    19c     21b     ST. (30 µg/mL)
  ---------------------------------- ------ -------------------- ------ ------ ------- ------- ----------------
  ***Fungi***                               **Amphotericin B**                                 
  ***Aspergillus niger***            0.98   3.9                  0.98   0.98   0.98    31.25   0.98
  ***Geotricum candidum***           0.98   1.95                 0.49   0.98   3.9     62.5    0.49
  ***G (^+^) Bacteria***                    **Ampicillin**                                     
  ***Staphylococcus aureus***        1.95   31.25                0.98   0.98   3.9     62.5    0.98
  ***Staphylococcus epidermidis***   3.9    31.25                1.95   7.81   7.81    1.95    1.95
  ***Bacillis subtilis***            0.98   62.5                 3.9    0.49   31.25   62.5    0.49
  ***Streptococcus pyogenes***       NA     NA                   NA     NA     NA      NA      0.49
  ***G (^−^) Bacteria***                    **Gentamicin**                                     
  ***Pseudomonas aeruginosa***       NA     NA                   NA     NA     NA      NA      1.95
  ***Escherichia coli***             0.98   7.81                 0.49   0.49   1.95    7.81    0.49
  ***Klebsiella pneumoniae***        1.95   3.9                  0.98   1.95   0.98    3.9     0.98
  ***Salmonella typhimurium***       0.49   0.49                 1.95   0.98   1.95    3.9     0.98
